Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Chunmei Bai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1333-9145; OpenAlex author ID A5028640794. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 4 papers

Papers 15

  1. Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large-Cohort Stud… Co-author DOI 10.1002/mco2.70829↗
  2. Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Co-author DOI 10.1038/s41392-026-02741-1↗
  3. Inhibition of Gemcitabine-Induced Autophagy in Cancer-Associated Fibroblasts Reduces Collagen I and Enhances Chemotherapeutic Efficacy in Pancreatic Cancer. Co-author DOI 10.1177/15473287261442512↗
  4. Adjuvant FOLFIRINOX versus S-1 monotherapy for resected PDAC: retrospective real-world data. Co-author DOI 10.1177/17588359261470681↗
  5. S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure. Last author DOI 10.1177/17588359251378698↗
  6. [Comparison of adjuvant S-1 plus gemcitabine with S-1 monotherapy for pancreatic adenocarcinoma: real-world data]. Last author DOI 10.3760/cma.j.cn112152-20250310-00103↗
  7. The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. Last author DOI 10.1007/s11764-023-01429-7↗
  8. A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenoca… Last author DOI 10.1186/s12885-023-11464-3↗
  9. Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma. Last author DOI 10.20892/j.issn.2095-3941.2023.0189↗
  10. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data. Last author DOI 10.1016/j.neo.2022.100841↗
  11. Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2147/cmar.s307079↗
  12. Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resecti… Last author DOI 10.3389/fonc.2021.660215↗
  13. CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection. Last author DOI 10.1016/j.pan.2019.01.023↗
  14. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma. Co-author DOI 10.1186/s12885-019-6372-z↗
  15. Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer. Last author DOI 10.3881/j.issn.1000-503x.2017.04.016↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuejuan Cheng · 12 shared papers, 2017–2026 · strength 2.31
  2. Tingting You · 7 shared papers, 2023–2026 · strength 1.86
  3. Hui Jun Tang · 6 shared papers, 2022–2026 · strength 1.35
  4. Yingyi Wang · 3 shared papers, 2025–2026 · strength 0.88
  5. Hui Tang · 3 shared papers, 2025–2026 · strength 0.87
  6. Yingyi Wang · 4 shared papers, 2022–2024 · strength 0.76
  7. Dongfeng Song · 2 shared papers, 2026 · strength 0.60
  8. Taiping Zhang · 2 shared papers, 2022–2026 · strength 0.41
  9. Robert Chunhua Zhao · 1 shared paper, 2026 · strength 0.32
  10. Menghua Dai · 2 shared papers, 2021–2022 · strength 0.26
  11. Jiangdong Qiu · 1 shared paper, 2026 · strength 0.26
  12. Wenhao Luo · 1 shared paper, 2026 · strength 0.26
  13. Hao Chen · 1 shared paper, 2026 · strength 0.26
  14. Zhe Cao · 1 shared paper, 2026 · strength 0.26
  15. Yupei Zhao · 1 shared paper, 2026 · strength 0.26
  16. Huanwen Wu · 1 shared paper, 2025 · strength 0.26
  17. Jiazhang Xing · 2 shared papers, 2019–2021 · strength 0.24
  18. Zhou Zhu · 1 shared paper, 2023 · strength 0.20
  19. Junchao Guo · 1 shared paper, 2022 · strength 0.16
  20. Jiarui Li · 1 shared paper, 2019 · strength 0.11
  21. Xinlun Tian · 1 shared paper, 2019 · strength 0.11
  22. Yuan Liu · 1 shared paper, 2019 · strength 0.11
  23. Ke Lv · 1 shared paper, 2021 · strength 0.10
  24. Qiang Xu · 1 shared paper, 2021 · strength 0.10
  25. Tongtong Zhou · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.